A
Aclaris Therapeutics, Inc. (ACRS)
NMS – Real Time Price. Currency in USD
3.52
0.00 (0.00%)
At close: Mar 27, 2026, 4:00 PM EDT
3.52
0.00 (0.00%)
After-hours: Mar 27, 2026, 4:10 PM EDT
Get all premium features to the best stock analysis tool
NMS – Real Time Price. Currency in USD
3.52
0.00 (0.00%)
At close: Mar 27, 2026, 4:00 PM EDT
3.52
0.00 (0.00%)
After-hours: Mar 27, 2026, 4:10 PM EDT
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
| Name | Position |
|---|---|
| Dr. Hugh M. Davis Ph.D. | President, COO & Director |
| Dr. Jon Jacobsen Ph.D. | Senior Vice President of Chemistry |
| Dr. Neal S. Walker D.O., M.D. | Co-Founder, CEO & Chairman |
| Dr. Roland Kolbeck Ph.D. | Chief Scientific Officer |
| Mr. Ajay Aggarwal M.B.A., M.D. | Senior Vice President of Clinical Development |
| Mr. James Loerop | Chief Business Officer |
| Mr. Kevin Balthaser | Chief Financial Officer |
| Mr. Matthew Rothman J.D. | General Counsel & Corporate Secretary |
| Mr. Steve Tucker | Executive Vice President of Project Leadership |
| Mr. William C. Roberts | Senior VP of Corporate Communications & Investor Relations |
| Date | Type | Document |
|---|---|---|
| 2026-03-11 | 8-K | acrs-20260310x8k.htm |
| 2026-03-10 | 8-K | acrs-20260309x8k.htm |
| 2026-01-12 | 8-K | acrs-20260112x8k.htm |
| 2026-01-06 | 8-K | acrs-20260106x8k.htm |
| 2025-11-06 | 10-Q | acrs-20250930x10q.htm |
| 2025-10-14 | 8-K | acrs-20251014x8k.htm |
| 2025-08-07 | 10-Q | acrs-20250630x10q.htm |
| 2025-07-29 | 8-K | acrs-20250729x8k.htm |
| 2025-06-30 | 8-K | acrs-20250630x8k.htm |
| 2025-06-05 | 8-K | acrs-20250605x8k.htm |